RT Journal Article
SR Electronic
T1 Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.30.21254652
DO 10.1101/2021.03.30.21254652
A1 Rémi Goupil
A1 Mehdi Benlarbi
A1 William Beaubien-Souligny
A1 Annie-Claire Nadeau-Fredette
A1 Debashree Chatterjee
A1 Guillaume Goyette
A1 Caroline Lamarche
A1 Alexander Tom
A1 Andrés Finzi
A1 Rita S. Suri
A1 on behalf of the Réseau Rénal Québécois (Quebec Renal Network) COVID-19 Study Investigators
YR 2021
UL http://medrxiv.org/content/early/2021/04/08/2021.03.30.21254652.abstract
AB Background Patients receiving in-center hemodialysis (HD) are at high risk of exposure to SARS-CoV-2 with high mortality, and response to vaccination is uncertain.Methods We obtained serial plasma from 58 HD patients and 32 health-care workers (HCW) before and after vaccination with one dose of the BNT162b2 mRNA vaccine; as well as convalescent plasma from 11 HD patients who survived COVID-19. Anti-RBD (region binding domain of the SARS-CoV-2 Spike protein) IgG and IgM levels were measured by ELISA. Groups were stratified by evidence of prior SARS-CoV-2 infection.Results In HD patients without prior SARS-CoV-2, antiRBD levels were significantly lower at 4 and 8 weeks after vaccination, compared to in HCWs after 3 weeks (p<0.001), and to convalescent plasma (p=0.002). Anti-RBD IgG was non-detectable in 29/46 (63%) of HD, compared to 1/16 (6%) of HCWs (p<0.0001). No patient with non-detectable levels at 4 weeks developed antiRBD by 8 weeks. In HD patients with prior SARS-CoV-2, mean 8-week anti-RBD IgG levels were similar to controls at 3 weeks (p=0.16), and to convalescent plasma (p=0.45). No patients reported symptoms 7 days after vaccination on a standardized questionnaire.Interpretation While the BNT162b2 vaccine was well-tolerated in hemodialysis patients, a single dose failed to elicit a humoral immune response in the majority of SARS-CoV-2 naïve patients even after prolonged observation. In those with prior SARS-CoV-2 infection, the humoral response after vaccination was delayed. Whether HD patients develop T-cell responses requires further study. Until then, we advise the second dose be administered to all HD patients at the recommended 3-week time interval, and that rigorous SARS-CoV-2 infection prevention and control measures be continued in dialysis units until vaccine efficacy is proven.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Canadian Institutes of Health Research (CIHR) Rapid Research COVID-19 funding opportunity. This work was also supported by le Ministère de l'Économie et de l'Innovation du Québec, Programme de soutien aux organismes de recherche et d'Innovation to AF, by the Fondation du CHUM and by a CIHR Foundation Grant #352417 to AF. RS, RG, ACNF, and WBS are supported by the Fonds de Recherche du Québec Santé (FRQS) Clinician-Researcher Awards. AF is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235950-232424.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comité d'éthique de la recherche clinique du CR-CHUM and l'Hôpital Sacre-CoeurAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified aggregate data is available upon request to the lead author, RS (rita.sur{at}mcgill.ca), provided the necessary institutional approvals are received. Further information on the assays used and requests for reagents should be directed to and will be fulfilled by AF (andres.finzi{at}umontreal.ca).